AGC
NVO

Aspen Grove Capital’s Novo Nordisk NVO Stock Holding History

Aspen Grove Capital’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,944
Closed -$203K – 234
2025
Q2 		$203K Sell
2,944
-1,279
-30% -$87K 0.03% 222
2025
Q1 		$298K Sell
4,223
-119
-3% -$9.83K 0.06% 164
2024
Q4 		$373K Buy
4,342
+49
+1% +$5.3K 0.08% 125
2024
Q3 		$511K Sell
4,293
-1
-0% -$133 0.11% 97
2024
Q2 		$613K Sell
4,294
-214
-5% -$28.4K 0.14% 84
2024
Q1 		$583K Hold
4,508
– – 0.16% 84
2023
Q4 		$466K Buy
4,508
+360
+9% +$35.6K 0.14% 88
2023
Q3 		$377K Buy
4,148
+62
+2% +$5.46K 0.14% 98
2023
Q2 		$331K Buy
4,086
+534
+15% +$43.6K 0.11% 137
2023
Q1 		$284K Sell
3,552
-2,524
-42% -$179K 0.12% 116
2022
Q4 		$411K Buy
+6,076
New +$356K 0.19% 90

Other funds holding NVO

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Aspen Grove Capital's NVO Position: Q3 2025 in Review

Aspen Grove Capital sold out of Novo Nordisk (NVO) in Q3 2025, closing a stake of 2,944 shares — an estimated $203K sold.

Aspen Grove Capital first reported a position in NVO in Q4 2022 and held it in 11 quarters. The position peaked at $613K in Q2 2024. 1,395 funds tracked by Wall St. Rank hold NVO as of Q3 2025.

  • Aspen Grove Capital reported no remaining Novo Nordisk position as of Q3 2025 after selling out during the quarter.
  • Aspen Grove Capital sold 2,944 Novo Nordisk shares in Q3 2025, an estimated $203K.
  • Aspen Grove Capital first reported a position in Novo Nordisk in Q4 2022 and held it in 11 quarters.
  • Aspen Grove Capital's Novo Nordisk position peaked at $613K in Q2 2024.
  • 1,395 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.

Based on Aspen Grove Capital's 13F filing for Q3 2025, filed 14 Nov 2025.